期刊文献+

A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan

原文传递
导出
摘要 Background:Approximately 10 million people in Pakistan are infected with the hepatitis C virus(HCV).Most patients develop chronic hepatitis,with rare cases of spontaneous clearance.However,little is known about multidrug resistant viral variants in Pakistan.Findings:This case study describes a 47-year-old male diagnosed with chronic HCV genotype 3a infection in 2003.After an initial diagnosis of viral infection,the patient remained treatment naïve for 5 years.He received two therapy cycles of interferon(IFN)plus ribavirin(RBV)in 2007 and 2010,however,he was non-responsive to the therapy.The patient then received an additional two treatment cycles of pegylated IFNα-2b plus RBV(in 2011 and 2013);he was still non-responsive.In 2016,the patient underwent sofosbuvir plus RBV combination therapy,however,the sustained virological response was still not achieved.The host genetic factor was found to be heterozygous guanine and thymine(GT)and cytosine and thymine(CT)genotypes of rs8099917 and rs12979860 polymorphism of IL28B,respectively.Phylogenetic analysis suggests that the resistant variant belong to an out-group and may require triple therapy.Conclusions:This is the first case that reports on a HCV-infected individual who was a non-responder to multiple IFN therapies in Pakistan.Further studies are needed to understand multidrug-resistant HCV variants in the Pakistani population.
出处 《Infectious Diseases of Poverty》 SCIE 2018年第1期123-128,共6页 贫困所致传染病(英文)
基金 AZ is supported by“Indigenous Ph.D.fellowship program”from the Higher Education Commission(HEC)of Pakistan.
  • 相关文献

参考文献1

二级参考文献155

  • 1Simmonds P. Genetic diversity and evolution of hepatitis Cvirus-15 years on. J Gen Virol 2004; 85: 3173-3188 [PMID:15483230 DOI: 10.1099/vir.0.80401-0]. 被引量:1
  • 2Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36: S21-S29 [PMID: 12407573 DOI: 10.1053/jhep.2002.36227]. 被引量:1
  • 3Pawlotsky JM. The nature of interferon-alpha resistance inhepatitis C virus infection. Curr Opin Infect Dis 2003; 16: 587-592[PMID: 14624110 DOI: 10.1097/01.qco.0000104300.87920.03]. 被引量:1
  • 4Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N,Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G,Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, PeninF, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, WeinerAJ, Widell A. Consensus proposals for a unified system ofnomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-973 [PMID: 16149085 DOI: 10.1002/hep.20819]. 被引量:1
  • 5Rosen HR, Gretch DR. Hepatitis C virus: current understandingand prospects for future therapies. Mol Med Today 1999; 5:393-399 [PMID: 10462751]. 被引量:1
  • 6Keyvani H, Fazlalipour M, Monavari SH, Mollaie HR. HepatitisC virus-proteins, diagnosis, treatment and new approachesfor vaccine development. Asian Pac J Cancer Prev 2012; 13:5931-5949 [PMID: 23464383]. 被引量:1
  • 7Hu KQ, Vierling JM, Redeker AG. Viral, host and interferonrelatedfactors modulating the effect of interferon therapy forhepatitis C virus infection. J Viral Hepat 2001; 8: 1-18 [PMID:11155147]. 被引量:1
  • 8Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis,management, and treatment of hepatitis C: an update. Hepatology2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]. 被引量:1
  • 9Kanda T, Imazeki F, Yokosuka O. New antiviral therapiesfor chronic hepatitis C. Hepatol Int 2010; 4: 548-561 [PMID:21063477 DOI: 10.1007/s12072-010-9193-3]. 被引量:1
  • 10European Association for the Study of the Liver. EASL ClinicalPractice Guidelines: management of hepatitis C virus infection.J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]. 被引量:1

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部